AXREM, the UK trade association representing suppliers of diagnostic medical imaging, radiotherapy, healthcare IT and related technologies, is pleased to announce the launch of its Regulatory and Policy Committee. This strategic initiative will enhance AXREM’s ability to monitor, respond to, and shape regulatory and policy developments affecting the MedTech sector.
The new committee will serve as a central hub for regulatory intelligence, consultation responses, and policy guidance, ensuring AXREM members are informed, aligned, and represented in key national and international forums. It will also support AXREM’s Special Focus Groups (SFGs) by providing expert advice on emerging regulatory issues and developments.
Sally Edgington, AXREM CEO, commented:” I am delighted to see the launch of our new Regulatory and Policy Committee. This is a significant step forward in strengthening the industry’s collective voice and ensuring our members are fully represented in the conversations that shape the future of healthcare technology.
Diagnostic imaging, radiotherapy, and healthcare IT are central to almost every patient pathway, and it is vital that the regulatory frameworks surrounding them are clear, supportive, and future-focused. By creating this committee, AXREM is not only enhancing our ability to respond to consultations and emerging issues, but also ensuring that our members’ expertise informs national and international policy discussions.
I look forward to working with the committee and our members to drive meaningful engagement with stakeholders such as MHRA, NICE, and BSI, and to continue positioning AXREM as a trusted partner to the NHS and government.
The committee will meet at least twice a year, with additional meetings convened in response to urgent consultations or emerging issues. It will be chaired by an elected member for a two-year term and supported by AXREM’s Membership Engagement Manager.
Key responsibilities of the committee include:
- Coordinating AXREM’s responses to government and regulatory consultations.
- Monitoring UK policy and regulatory developments relevant to the MedTech sector.
- Advising the AXREM Executive Committee on strategic regulatory matters.
- Appointing representatives to external organisations and working groups.
The committee will also oversee AXREM’s engagement with bodies such as MHRA, NICE, BSI, and other regulatory stakeholders, ensuring member interests are effectively represented.
For more information about the Regulatory and Policy Committee, including membership and delegated authorities, please visit www.axrem.org.uk.
Note:
AXREM members supply the majority of diagnostic medical imaging and radiotherapy equipment installed in UK hospitals. In doing so, our member companies and their employees work side by side with Radiologists, Radiographers, Practitioners, Oncologists and a wide range of healthcare professionals in delivering healthcare to patients using our technologies.
Our members therefore have unique knowledge, experience and insight into the workflow and challenges faced by healthcare professionals on a day-to-day basis, which enables us to develop and offer innovative solutions to improve the speed and quality of diagnostic procedures and treatments with our ultimate aim of improving patient care.
Although our members operate in a highly competitive commercial environment and in strict conformity with UK laws and regulations, certain issues such as this require focus and resolution on an industry-wide basis.
For further information about this press release please contact AXREM Chief Executive Officer – Sally Edgington
AXREM, Rotherwick House, 3 Thomas More Street, London, E1W 1YZ
E sally.edgington@axrem.org.uk
T 07717 058649
